Clinical trial
A Phase 1, Open-label Study Evaluating the Pharmacokinetic Drug-drug Interactions Between VX-993 and Metformin in Healthy Adult Subjects
NCT06523595 is registered in ClinicalTrials.gov with Vertex Pharmaceuticals Incorporated as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Open-label Study Evaluating the Pharmacokinetic Drug-drug Interactions Between VX-993 and Metformin in Healthy Adult Subjects
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- July 31, 2024
- Completion date
- December 31, 2024
- Enrollment
- 31 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.